Want to see BRKR full AI Analyst Report?
Top Page
Bruker
(NASDAQ:BRKR)
Select Model
Select Model
Rating:61Neutral
Price Target:
$65.00
▲(7.53% Upside)
Action:Reiterated
Date:07/31/26
BRKR scores as a balanced setup driven mainly by mixed financial performance: strong revenue history and positive free cash flow are outweighed by the recent profitability reset and slightly negative net income/ROE. Technicals add support with price above key moving averages, while valuation is a clear drag due to the negative P/E and low dividend yield. Earnings-call commentary is moderately supportive on reconfirmed FY26 guidance, strong bookings, and accelerated cost savings, but near-term organic declines and China/academic weakness remain meaningful risks.
Positive Factors
Recurring Aftermarket & Services
Bruker’s installed base drives recurring consumables, service contracts and software sales that stabilize revenue and cash flow through capital spending cycles. That aftermarket pull-through enhances customer retention and margin sustainability, providing durable, predictable revenue even if instrument orders fluctuate.
Negative Factors
Margin & Profitability Erosion
Margins have materially compressed and the company reported slight net losses in 2025 and TTM, eroding returns and internal funding capacity. Sustained margin weakness reduces free cash available for R&D, buybacks or deleveraging, and increases execution risk as management must restore structural profitability rather than rely on one-off fixes.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Aftermarket & Services
Bruker’s installed base drives recurring consumables, service contracts and software sales that stabilize revenue and cash flow through capital spending cycles. That aftermarket pull-through enhances customer retention and margin sustainability, providing durable, predictable revenue even if instrument orders fluctuate.
Read all positive factors
Bruker Key Performance Indicators (KPIs)
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.57B
Dividend Yield0.32%
Average Volume (3M)1.93M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth0.36%
EPS Growth-145.55%
CountryUS
Employees11,085
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding152,225,620
10 Day Avg. Volume1,792,076
30 Day Avg. Volume1,933,707
Financial Highlights & Ratios
PEG Ratio2.62
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio514.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$56.67Price Target Upside-6.26% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.59B
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segme...
How the Company Makes Money
Bruker primarily makes money by selling high-performance scientific instruments and related solutions to academic institutions, pharmaceutical and biotechnology companies, industrial manufacturers, and clinical/diagnostic customers. Its revenue mo...
Bruker Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call presents a cautiously constructive picture: management beat Q1 expectations, highlighted multiple high-growth, AI-driven and idiosyncratic end-market opportunities (Semi Metrology, SciY, security detection, BEST superconductors), and is delivering cost savings above original targets while reconfirming full-year guidance. These positives are balanced against meaningful near-term organic revenue declines, China and academic funding weaknesses, margin and mix pressures, and EPS softening in Q1. On balance, the positive operational momentum (strong bookings, large multi-year orders, and expanded cost savings) and reconfirmed guidance slightly outweigh the current headwinds.Positive Updates
Reported Revenue Beat
Q1 reported revenue $823.4M, up 2.7% year-over-year (FX tailwind +4.5%, M&A +2.6%, organic -4.4%) and came in ahead of prior expectations.
Negative Updates
Organic Revenue Decline
Q1 organic revenue decreased 4.4% year-over-year; BSI segment revenues down ~5% organically and BioSpin CER revenue declined in the high-single-digits.
Read all updates
Q1-2026 Updates
Positive
Negative
Reported Revenue Beat
Q1 reported revenue $823.4M, up 2.7% year-over-year (FX tailwind +4.5%, M&A +2.6%, organic -4.4%) and came in ahead of prior expectations.
Read all positive updates
Company Guidance
Bruker reconfirmed its full‑year 2026 guidance: reported revenue $3.57B–$3.60B (reported growth 4%–5% vs FY25) with organic revenue growth of 1%–2%, acquisitions contributing ~1.5% and an estimated FX tailwind of ~1.5%; it expects organic non‑GAAP operating margin expansion of 300–350 bps (netting to a 250–300 bps improvement vs FY25’s 12.6% after an ~50 bp FX headwind) and non‑GAAP EPS of $2.10–$2.15 (15%–17% reported growth; an ~8% FX headwind implies CER EPS growth of 23%–25%). Management said Q2 should return to organic revenue growth (low‑ to mid‑single digits) with a meaningful sequential step‑up in non‑GAAP operating margin and EPS as tariff/FX laps ease, citing Q1 as a strong start (Q1 revenue $823.4M, +2.7% reported; organic –4.4%; M&A +2.6%; FX +4.5%; BSI organic bookings high‑single‑digits; BSI book‑to‑bill >1.0x) and Q1 non‑GAAP gross and operating margins of 50% and 10.2%, Q1 non‑GAAP EPS $0.31, while tracking roughly $140M of annualized cost savings (up from a $100–120M target).Bruker Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.46B | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.58B | 1.58B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 302.70M | 302.60M | 438.60M | 675.50M | 518.70M | 497.10M |
| Net Income | -11.60M | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | ||||||
| Total Assets | 6.13B | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 133.40M | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 1.67B | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.63B | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.45B | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 51.30M | 13.90M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 140.30M | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -210.10M | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | -18.60M | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Positive
60.45
Price Trends
57.54
Positive
47.72
Positive
45.70
Positive
Market Momentum
1.23
Positive
55.19
Neutral
75.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 60.45 is above the 20-day moving average (MA) of 60.16, above the 50-day MA of 57.54, and above the 200-day MA of 45.70, indicating a bullish trend. The MACD of 1.23 indicates Positive momentum. The RSI at 55.19 is Neutral, neither overbought nor oversold. The STOCH value of 75.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $10.69B | 18.11 | 13.04% | ― | 23.49% | 219.12% | |
71 Outperform | $4.40B | 40.68 | 9.13% | ― | 12.40% | ― | |
66 Neutral | $8.72B | 53.27 | 2.40% | ― | 1.92% | ― | |
66 Neutral | $4.12B | 29.85 | 8.23% | ― | 5.48% | 77.43% | |
64 Neutral | $9.83B | -51.30 | -27.07% | ― | 41.55% | -96.75% | |
61 Neutral | $9.57B | -262.93 | -0.51% | 0.33% | 0.36% | -145.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BRKR
Bruker
62.84
28.30
81.92%
BIO
Bio-Rad Laboratories
325.48
48.68
17.59%
ITGR
Integer Holdings
121.21
14.38
13.46%
GMED
Globus Medical
78.79
25.16
46.91%
GKOS
Glaukos
166.72
79.22
90.54%
LIVN
LivaNova
80.14
37.38
87.42%
Bruker Corporate Events
Business Operations and StrategyDividends
Bruker Declares Quarterly Dividend on Mandatory Convertible Preferred
Positive
Jul 30, 2026
On July 30, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, with a par value of $0.01 per share. The dividend is scheduled t...
Executive/Board ChangesShareholder Meetings
Bruker Shareholders Reelect Directors and Approve Governance Items
Positive
May 21, 2026
At its 2026 Annual Meeting of Stockholders held on May 21, 2026, Bruker Corporation’s shareholders elected Laura A. Francis, John J. (Jack) Phillips and Hermann F. Requardt, Ph.D. as Class II directors to serve three-year terms ending at the...
Dividends
Bruker Declares Quarterly Cash Dividend, Signaling Ongoing Confidence
Positive
May 15, 2026
On May 14, 2026, Bruker Corporation’s board of directors declared a quarterly cash dividend of $0.05 per share on its common stock, with a par value of $0.01 per share. The dividend is scheduled to be paid on July 7, 2026, to shareholders of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.